EGFR and non-small cell lung carcinoma: The incidence of grade ≥3 adverse events and specific neurotoxicities was low and comparable between groups.<h4>Conclusion</h4>For patients with EGFR-mutant NSCLC and synchronous BM, early brain radiotherapy combined with first-line third-generation EGFR-TKIs is associated with significantly improved intracranial control and overall survival compared to deferring radiotherapy until progression, without a significant increase in severe toxicity.